Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 12/20 | 0.56 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5700188 | 0.83 | NFE2L2 (0.58) | NFE2L2PLAUPDGFRBPDGFRAALDH1A1 | |
| SCHEMBL22831254 | 0.81 | NFE2L2 (0.56) | NFE2L2PLAUPDGFRBPDGFRAALDH1A1 | |
| SCHEMBL27573239 | 0.81 | NFE2L2 (0.56) | NFE2L2PLAUPDGFRBPDGFRAALDH1A1 | |
| SCHEMBL27326888 | 0.80 | NFE2L2 (0.55) | NFE2L2PLAUPDGFRBPDGFRAALDH1A1 | |
| SCHEMBL30876165 | 0.80 | NFE2L2 (0.55) | NFE2L2PLAUPDGFRBPDGFRAALDH1A1 | |
| SCHEMBL3721266 | 0.79 | NFE2L2 (0.54) | NFE2L2PLAUPOLB | |
| Ammonia Solution, Strong SCHEMBL29260132 | 0.79 | NFE2L2 (0.54) | NFE2L2PLAUPDGFRBPDGFRAALDH1A1 | |
| SCHEMBL28845135 | 0.76 | NFE2L2 (0.41) | NFE2L2ALDH1A1TRPV4 | |
| SCHEMBL3003594 | 0.75 | LTA4H (0.55) | SLC40A1 | |
| SCHEMBL27858431 | 0.75 | TRPV4 (0.48) | NFE2L2TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025136811-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | IDEAYA BIOSCIENCES, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2022109001-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | NFE2L2 923/4885PLAU 3887/4885PDGFRB 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.